相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Newer monoclonal antibodies for hematological malignancies
Jorge Castillo et al.
EXPERIMENTAL HEMATOLOGY (2008)
Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide
Jiamu Du et al.
MOLECULAR IMMUNOLOGY (2008)
Novel and engineered anti-B-Cell monoclonal antibodies for non-Hodgkin's lymphoma
Peter Martin et al.
SEMINARS IN HEMATOLOGY (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Evaluation of the binding of radiolabeled rituximab to CD20-Positive lymphoma cells:: An in vitro feasibility study concerning low-dose-rate Radioimmunotherapy with the α-emitter 227Th
Katrine B. Melhus et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Cardiac primitive neuroectodermal tumor presenting as acute coronary syndrome
Senthil Rajappa et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab
Josette Carnahan et al.
MOLECULAR IMMUNOLOGY (2007)
Epratuzumab in the therapy of oncological and immunological diseases
David M. Goldenberg
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
Sandra J. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor
F Perosa et al.
BLOOD (2006)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Depletion of B cells by a humanized Anti-CD20 antibody PRO70769 in Macaca fascicularis
Y Vugmeyster et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
R Stein et al.
CLINICAL CANCER RESEARCH (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure
MJ Polyak et al.
BLOOD (2002)
分享论文
